Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma

Jennifer L. Beaumont*, John M. Salsman, Jose Diaz, Keith C. Deen, Lauren McCann, Thomas Powles, Michelle D. Hackshaw, Robert J. Motzer, David Cella

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences